Document Detail

Current management and perspectives for HCV recurrence after liver transplantation.
MedLine Citation:
PMID:  23286847     Owner:  NLM     Status:  In-Data-Review    
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries. All patients who undergo LT with detectable serum HCV RNA experience graft reinfection. Between 20 and 30% of patients develop cirrhosis within 5 years post-LT. The outcome of transplant patients with cirrhosis on the graft is severe, with a rate of decompensation at 1 year of around 40%. To date, retransplantation is the only option for patients who develop decompensation. Until 2011, standard antiviral therapy, using pegylated interferon (PEG-IFN) and ribavirin (RBV), was the only effective therapy. Obtaining a sustained virological response (SVR) in the setting of LT greatly improves overall and graft survival, but this only concerns 30% of transplanted patients. Direct-acting antivirals (DAA) such as protease inhibitors, polymerase or other non-structural proteins inhibitors represent a new era in HCV-associated liver disease. Although their use in the field of liver transplantation seems to be essential, there are some limitations due to safety and tolerance. One limitation is the potential interaction with calcineurin inhibitors. We describe the preliminary results of triple therapy with boceprevir or telaprevir in terms of efficacy and safety in liver transplant recipients.
Audrey Coilly; Bruno Roche; Didier Samuel
Related Documents :
24017987 - Facial hair restoration: hair transplantation to eyebrows, beard, sideburns, and eyelas...
25017077 - Hepatitis viruses and liver transplantation: evolving trends in antiviral management.
23253557 - Transplant-related mortality, graft failure and survival following reduced toxicity con...
8980287 - Human papillomavirus dna in non-melanoma skin cancers of a renal transplant recipient: ...
564007 - Renal anomalies in the "xy female".
19715937 - Prophylaxis and treatment of cytomegalovirus infection postrenal transplantation in two...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  33 Suppl 1     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  56-62     Citation Subset:  IM    
Copyright Information:
© 2012 John Wiley & Sons A/S.
AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France; UMR-S 785, Univ Paris-Sud, Villejuif, France; Inserm, Unit 785, Villejuif, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Next Document:  HCV therapy in HIV-infected patients.